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Results: Figure 1 displays the mean differences of the dose 
metrics between repeated CT and CBCT, for Varian and 
Elekta CBCT scans. For Varian, a good agreement between 
the dose distributions recalculated on CBCT and repeated CT 
was observed when a thorax-specific HU-ED table was used. 
For Elekta, the dose metrics showed larger deviations with 
the thorax-specific HU-ED table, however, using a patient-
specific HU-ED table resulted in similar accuracy as for Varian 
CBCT dose calculations. Differences between repeated CT 
and CBCT dose metrics were below 3% for both vendors.  
 
 
Conclusion: Differences between Elekta and Varian CBCT, 
including hardware, reconstruction software, HU calibration, 
FOV and scan length, resulted in different challenges for 
CBCT dose calculations for the different vendors. For Elekta 
CBCT scans, the procedure with a patient-specific HU-ED 
table resulted in similar accuracy as for Varian CBCT dose 
calculations with a general HU-ED correction for all thorax 
patients, but is more time-consuming. The vendor-specific 
corrective methods used in this study, resulted in dose 
calculations feasible for treatment re-evaluation for both 
Elekta and Varian CBCT scans. 
References: 1.Yang et al. PhysMedBiol 2007, 2.Richter et al. 
RadOnc 2008, 3. Hatton et al. PhysMedBiol 2009, 4.Fotina et 
al. RadiotherOnc 2012, 5. Dunlop et al. StrahlentherOnkol 
2015 
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Purpose or Objective: At our department, patients with cT1-
2aN0M0 laryngeal cancer are treated with volumetric-
modulated arc therapy (VMAT). The treatment plan quality is 
monitored by plan evaluations on weekly repeat CTs. The 
purpose of this study was to determine plan quality during 
treatment by recalculating the actually given dose based on 
repeat CT.  
 
Material and Methods: Three patients treated with 
accelerated radiotherapy (66-70 Gy in 2 Gy fractions) were 
selected because of over dosages exceeding 78 Gy at the 
transition from air to tissue. Each clinical VMAT plan (plan I) 
was optimized towards homogeneous dose distributions in the 
planning target volumes (PTV) and low as possible dose to the 
critical organs such as the swallowing organs at risk. The 
treatment plan quality was evaluated using weekly repeat 
CTs. In addition, two more treatment plans were made 
including a density override of 0.5 g.cm-3 for the PTV-in-air 
overlap region (plan II), and the PTV-in-air + 5 mm region 
(plan III). All plans were evaluated with the PTV-in-air region 
assigned a density override value of 0.0 and 1.0 g.cm-3 to 
simulate the initial planning scenario and to simulate 
extension of CTV-in-air, resp. Finally, the “actual given dose” 
of the clinical target volume (CTV) was estimated by 
accumulated repeat CT dose evaluations. 
 
Results: The repeat CTs showed an extending CTV towards 
the laryngeal air cavity over the course of treatment. Repeat 
CT evaluations indicated increasing max doses up to 80 Gy. 
Evaluation of plan I on the initial planning CT, using a density 
override of 1.0 g.cm-3, showed a potential dose hotspot with 
similar max dose values (80-87 Gy). When no density override 
was assigned the PTV (D98%) coverage of plan I was 
sufficient. In contrast, plan II and III showed slightly to 
moderate PTV under dosage (65 Gy), albeit within the PTV-
in-air region. However, the accumulated CTV dose (D100) 
demonstrated no clinically relevant under dosage in the CTV 
(methods plan II: 67.4 Gy and plan III 65.2 Gy). Furthermore, 
the plan optimization approach as used in plan II and III 
resulted in reduced and acceptable max dose values within 
the targets (76.9 Gy and 74.3 Gy, resp).  
 
Conclusion: Unacceptable high doses of up to 80 Gy were 
observed in VMAT plan evaluations based on weekly repeat 
CTs. To avoid these over dosages, high fluence profiles in 
PTV-in-air regions should be avoided during planning 
optimization. An alternative VMAT optimization and 
evaluation approach has been proposed for cT1-2aN0M0 
laryngeal cancer patients. 
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Purpose or Objective: At the Leeds Cancer Centre 
approximately 40% of lung patients receiving VMAT 
radiotherapy (RT) display a reduction in tumour volume when 
imaged using CBCT during treatment. The aim of this work 
was to develop a method to assess whether the dosimetric 
impact of observed anatomical changes is sufficiently 
significant to justify a treatment replan. 
 
Material and Methods: Twelve lung patients receiving FFF 
VMAT RT planned on the Monaco 3.3 treatment planning 
system (Elekta) were identified. All had been rescanned, 
recontoured and replanned due to noted tumour shrinkage. 
For lung replans the clinical aim is to continue treating the 
original target volumes, so a rigid registration was performed 
between the planning CT and the rescan CT using a mutual 
information algorithm. Target volumes and OAR were 
transferred from the planning CT to the rescan CT and 
assessed by a physicist and clinician team to ensure they 
were clinically appropriate. The original plan was 
recalculated on the rescan CT studyset and dose volume 
histogram (DVH) statistics calculated for targets and OARs on 
the rescan studyset. 
 
Results: For patients who displayed tumour changes without 
other significant internal changes the transferred target 
structures were deemed clinically acceptable with minor 
editing. Comparison of the transferred structures to the 
replan structures indicated that differences in remarking the 
targets were larger than image registration and transferral 
errors. Small variations in spinal cord and lung contours 
suggest that it is more accurate to re-contour these 
structures on the rescan CT, especially if they are receiving a 
dose close to tolerance. This method of adaptive planning 
was found to significantly reduce the replanning time. A 
notable limitation of the process was observed for patients 
who display other significant internal anatomical changes 
such as a change in lung volume or mediastina position, 
resulting in inaccurate transferred structures. Based on the 
DVH statistics for the transferred targets and re-contoured 
OAR, 9/12 plans required a full treatment replan. Although 
the target coverage was clinically acceptable the loss of 
tumour tissue meant that nearby OAR received doses above 
their tolerance. 
 
